c-RET
The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively. Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.
製品は c-RET
- Cat.No. 商品名 インフォメーション
-
GC16362
AD57 (hydrochloride)
RETを抑制する多剤作用がん治療薬。
-
GC16391
Amuvatinib (MP-470, HPK 56)
HPK56, MP470
多標的RTK阻害剤
-
GC15217
Danusertib (PHA-739358)
PHA-739358
パン・オーロラキナーゼとAbl阻害剤
-
GC14606
Regorafenib hydrochloride
多機能キナーゼ阻害剤
-
GC14534
Regorafenib monohydrate
多機能キナーゼ阻害剤
-
GC13194
RPI-1
RPI-1 は、特定の経口投与可能な 2-インドリノン Ret チロシンキナーゼ阻害剤です。 RPI-1 は、ヒト甲状腺髄様癌 TT 細胞の増殖、Ret チロシンリン酸化、Ret タンパク質発現、および PLCgamma、ERK、AKT の活性化を阻害します。抗腫瘍活性。
-
GC15307
SU5416
NSC 696819, Semaxinib, Sugen 5416, VEGFR 2 Kinase Inhibitor
チロシンキナーゼ阻害剤
-
GC10035
TG101209
JAK2、FLT3、RET、およびJAK3の阻害剤